Skip to main
CNTB

CNTB Stock Forecast & Price Target

CNTB Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Connect Biopharma Holdings Ltd demonstrates a strong potential for growth due to the encouraging clinical efficacy results of its drug candidates, particularly with crossover patients witnessing 52-week improvements in IGA and EASI metrics, indicating significant therapeutic benefits. Additionally, the ongoing development of rademikibart via IV dosing could enhance its efficacy in acute settings, with clinical data anticipated around the end of 2025, further solidifying the company's innovative pipeline. The expectation of meaningful market uptake following these efficacy advancements and the critical timing associated with treatment underscores a positive outlook for the company's future performance in the competitive biopharmaceutical sector.

Bears say

Connect Biopharma Holdings Ltd faces significant challenges due to potential complications associated with dupilumab, including hyper-eosinophilia, which may deter its use in treatment settings and could limit the drug's marketability. The impending expiration of regulatory exclusivity and intellectual property protection for Dupixent, anticipated in 2029 and 2031, raises concerns about future revenue streams and the lack of new development efforts from Sanofi/Regeneron in light of high time and cost requirements. Additionally, expected resistance from payors regarding the use of dupilumab in acute settings due to insufficient clinical trial evidence further complicates its commercial viability.

CNTB has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Connect Biopharma Holdings (CNTB) Forecast

Analysts have given CNTB a Strong Buy based on their latest research and market trends.

According to 3 analysts, CNTB has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Connect Biopharma Holdings (CNTB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.